Phase I trial of bortezomib daily dose: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors.
Rastislav Bahleda
No relevant relationships to disclose
Marie-Cécile Le Deley
No relevant relationships to disclose
Apexa Bernard
No relevant relationships to disclose
Shalini Chaturvedi
No relevant relationships to disclose
Anas Gazzah
No relevant relationships to disclose
Andrea Varga
No relevant relationships to disclose
Chi Keung
No relevant relationships to disclose
Eric Deutsch
No relevant relationships to disclose
Christophe Massard
No relevant relationships to disclose
Helgi Van De Velde
No relevant relationships to disclose
Antoine Hollebecque
No relevant relationships to disclose
Eric Angevin
No relevant relationships to disclose
Vincent Ribrag
No relevant relationships to disclose
Jean-Charles Soria
No relevant relationships to disclose